Daratumumab achieves 29.2{c754d8f4a6af077a182a96e5a5e47e38ce50ff83c235579d09299c097124e52d} overall response rate in heavily pre-treated patients with multiple myeloma
Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95{c754d8f4a6af077a182a96e5a5e47e38ce50ff83c235579d09299c097124e52d} CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.
Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95{c754d8f4a6af077a182a96e5a5e47e38ce50ff83c235579d09299c097124e52d} CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.
SOURCE: The Medical News – Read entire story here.